GET
TO KNOW
OUR TEAM

Amit is a 30+ year industry veteran who is passionate about developing transformative medicines. Amit was most recently President and CEO of Arena Pharmaceuticals Inc. (Nasdaq:ARNA) where he built the company from a $300M market cap into a late clinical stage company with 37 programs, 4 drugs, and 11 indications before their $6.7B acquisition by Pfizer.

Peter has over 30+ years of industry experience and is a proven leader in early drug discovery and development having held key senior roles at Alnylam Pharmaceuticals, Moderna Therapeutics, and Millennium Pharmaceuticals where he has led the development of numerous NDAs and BLAs including several in the RNA space. He has a unique set of experience building and leading teams across multiple RNA modalities and delivery platforms.

Brian has 20+ years of experience in healthcare corporate development including leadership positions at JPMorgan where he was involved in 15 M&A transactions and 30 financings for biotech and pharmaceutical clients. Additionally, he held leadership positions at Johnson & Johnson where he executed 25 strategic transactions.

Ciaran has deep experience in building and leading teams across biotech and consulting sectors. He recently held principal leadership role at The Boston Consulting Group where he led large projects / programs across corporate strategy, R&D operations, M&A, and commercial. Ciaran was previously an early scientific lead at Moderna where he helped build out delivery capabilities.

Laurie has over 25 years of experience supporting the finance functions for biopharma companies, most recently as CFO of Mirati Therapeutics. Previously, she served as CFO of Arena Pharmaceuticals, where she helped lead the growth of the company toward its $6.7B acquisition by Pfizer. She was also CFO at Halozyme Therapeutics, where she led the company’s finance, IT, business development, and project management functions. She also held senior management roles at Shire, including Senior Vice President of Finance, Division CFO for the Regenerative Medicine Division, and Head of Investor Relations. She began her biotech career at Amgen, where she spent 15 years in positions of increasing responsibility, holding multiple roles in finance, global commercial operations, treasury and international/emerging markets. Laurie received her B.S. in Accounting from Arizona State University and her M.B.A. from the Anderson School of Management at the University of California, Los Angeles.

Joe has more than 45 years of industry and research experience. He is an Executive  Partner at MPM BioImpact and was formerly Chief Scientific Officer at PureTech Health. Before joining PureTech, he oversaw all aspects of research and development for Moderna Therapeutics as President of Research & Development and Chief Scientific Officer. Previously, Joe was Chief Scientific Officer at Millennium Pharmaceuticals and Global Head of Oncology Research at Takeda Pharmaceutical Company. He held senior R&D positions at Hoechst Marion Roussel, Schering-Plough (DNAX) and Bristol Myers Squibb. Joe began his career at the National Institutes of Health (NIH), where he contributed to the discovery of a class of proteins known as tyrosine kinase oncogenes as key regulators of the immune system. Joe earned a Ph.D. in Immunology and conducted his postdoctoral training in molecular virology at Kansas State University Cancer Center. He graduated from the University of Nebraska with a B.S. in Microbiology and Chemistry.